(Q45950594)

English

Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen.

scientific article published on 24 June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Shigella flexneri

1 reference

based on heuristic

inferred from title

oligosaccharide

1 reference

based on heuristic

inferred from title

author name string

Fatouma Said Hassane

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Armelle Phalipon

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Myriam Tanguy

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Catherine Guerreiro

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Frédéric Bélot

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Benoît Frisch

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Laurence A Mulard

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Francis Schuber

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

language of work or name

0 references

publication date

24 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

27

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

39

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

5419-5426

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Haemophilus influenzae type b conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Conjugates and reverse vaccinology to eliminate bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Recent developments in synthetic oligosaccharide-based bacterial vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Nanocarriers for systemic and mucosal vaccine delivery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Liposomes as carriers of antigens and adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Engineering liposomes for drug delivery: progress and problems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Induction of immune response against a short synthetic peptide antigen coupled to small neutral liposomes containing monophosphoryl lipid A

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Trafficking of surface-linked and encapsulated liposomal antigens in macrophages: an immunocytochemical study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Endocytosis and presentation of liposome-associated antigens by B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Activating B Cell Signaling with Defined Multivalent Ligands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

The macrophage-activating lipopeptide-2 accelerates wound healing in diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Targeted liposomes: convenient coupling of ligands to preformed vesicles using "click chemistry"

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Fluorometric assay of proteins in the nanogram range

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

The contribution of immunology to the rational design of novel antibacterial vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Liposomal vaccines--targeting the delivery of antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Differential reactivity of maleimide and bromoacetyl functions with thiols: application to the preparation of liposomal diepitope constructs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Peptide vaccines and peptide libraries

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Lipopeptides: adjuvanticity in conventional and genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Towards a Fully Synthetic Carbohydrate-Based Anticancer Vaccine: Synthesis and Immunological Evaluation of a Lipidated Glycopeptide Containing the Tumor-Associated Tn Antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Robust immune responses elicited by a fully synthetic three-component vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Synthetic carbohydrate-based vaccines: synthesis of an L-glycero-D-manno-heptose antigen–T-epitope–lipopeptide conjugate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

A carbohydrate vaccine exceeds the sum of its parts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Liposomal adjuvanticity: effect of encapsulation and surface-linkage on antibody production and proliferative response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Liposomal vaccine: influence of antigen association on the kinetics of the humoral response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Lipopeptide vaccines--yesterday, today, and tomorrow

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

Thymus-independent and thymus-dependent responses to polysaccharide antigens

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.031

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.06.031

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19559116

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45950594&oldid=1477735764"